NEW YORK – (DGIwire) — Type 2 diabetes currently afflicts more than 371 million people worldwide, according to the International Diabetes Federation. The number of people diagnosed with Type 2 diabetes each year is increasing in every country, with about half of all patients being prediabetic and not even knowing they have the disease until it’s too late.
In Australia, which already has 1.5 million people living with the disease, according to the nonprofit diabetes advocacy organization Diabetes Australia, Type 2 diabetes is expected to be the country’s number one cause of death within five years. What’s more, the organization reports, an estimated three million Australians will be affected by 2025. Recent studies also show that young people with the more preventable Type 2 diabetes are twice as likely to die from the disease as those with Type 1.
Fortunately, living with diabetes doesn’t have to be an invasive burden—there is reason for hope, thanks to a new glucose measurement device called GlucoTrack® Model DF-F. This device, developed by Integrity Applications, an Israeli-based medical device company, is expected to be distributed throughout Australia and New Zealand exclusively through Ultramedix Australasia Pty Ltd, subject to the approval of the listing of the GlucoTrack model DF-F device on the Australian Register of Therapeutic Goods (ARTG) register.
GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking three measurements. The measurements are analyzed using a proprietary algorithm and the weighted average glucose level is displayed on a portable handheld device, the size of a mobile phone. The blood glucose measurement is also announced verbally, making it suitable for elderly and vision-impaired patients. The company obtained a CE Mark for its GlucoTrack Model DF-F in Europe in June 2013 and intends to seek Food and Drug Administration approval for GlucoTrack in the United States.
Avner Gal, President and CEO of Integrity Applications, said, “This distribution agreement—expected to be followed by others in other countries—marks an important milestone for our company. We look forward to providing diabetes patients throughout Australia and New Zealand with this new, noninvasive option for measuring blood glucose.”